NTrans Technologies BV, based in Utrecht, The Netherlands, is a cutting-edge company founded in 2015. They specialize in intracellular delivery of bioactive molecules using their proprietary platform technology. Developed at the prestigious Hubrecht Institute of the Royal Netherlands Academy of Sciences, their platform is safe, non-toxic, highly efficient, and user-friendly.

NTrans Technologies aims to be a frontrunner in the field of transduction of proteins and other bioactive molecules into primary cells. With a focus on research and clinical purposes, NTrans Technologies offers licensing of their unique transduction platform. They provide thorough technical support to optimize the transduction process.

Their dedicated team of experts ensures that clients receive the best possible results. Notable achievements include the completion of the H2020-ENTRANCE project, where NTrans Technologies optimized the composition of their iTOP technology and developed protocols for effective transfection of various cell types. They were also awarded the prestigious BCF Scale-up Award in 2019, solidifying their reputation as a standout gene editing therapy company.

For more information about NTrans Technologies BV and their innovative solutions, visit their website at www. ntranstechnologies. com